BNT162b2 mRNA vaccine in transfusion dependent thalassemia patients

Abstract

We would like to comment on 'Efficacy and safety of BNT162b2 mRNA vaccine in a cohort of 90 transfusion dependent thalassemia patients'. 1 Ninety individuals with thalassemia who were reliant on transfusions were used to assess the safety and effectiveness of the BNT162b2 mRNA vaccination. The majority of the patients experienced a good antibody response following vaccination, indicating